SQ-LIP-000036 · v1.1 (current) · machine-readable JSON →
Is lipedema onset influenced by heredity and family history?
Multiple studies consistently show that lipedema runs in families and that genetic factors contribute to its onset, with genome-wide studies identifying several candidate regions and supporting a hereditary component, most likely through an autosomal dominant pattern with incomplete expression in males. The exact genes responsible have not been confirmed, family-history estimates vary wildly across studies (15–89%) due to methodological differences, and it is unclear whether the genetic signals found are specific to lipedema or shared with general fat distribution traits.
- Current answer
- Lipedema onset appears to be influenced by heredity and family history, though the evidence is predominantly descriptive and the precise genetic architecture remains undefined.
- Knowledge state
- Emerging · Evidence confidence: very low (GRADE) · Stability: Evolving
- Evidence
- 21 consistent · 0 conflicting · 0 refining / contextual
- ⚠ none indexed yet — the registry may under-detect disconfirming evidence (a known limitation)
- Main limitation
- The mode of inheritance and causal genes are unresolved: family-history prevalence estimates vary enormously (15–89%) across mostly descriptive, unadjusted cross-sectional…
- Latest change
- Answer recompiled after human curation of the claim set. · v1.1
- Knowledge freshness
- 71% recent · current evidence base
- Last updated
- 2026-06-02 · v1.1
Based on currently indexed evidence, lipedema onset appears to be influenced by heredity and family history, though the evidence is predominantly descriptive and the precise genetic architecture remains undefined. Multiple sources consistently report frequent positive family history among affected women, with reported familial prevalence ranging widely across studies (≈15% of first-degree relatives in one systematic review; 14.9% with an affected first-degree relative in a 67-proband series; 46% in a Saudi cross-sectional study; and up to 60–64% suggesting autosomal dominant inheritance in some reviews; broader review estimates span 30–89%). Affected relatives are almost exclusively female, and several pedigree/linkage analyses favor autosomal dominant inheritance with incomplete penetrance and sex limitation, while X-linked dominant inheritance was excluded in one family. The strongest-quality evidence comes from genome-wide association studies: a GWAS of an inferred lipedema phenotype in UK Biobank (moderate grade) reported SNP heritability of ~5.13% and 18 genome-wide significant loci (e.g., RSPO3, GRB14-COBLL1, VEGFA, ADAMTS9), and a dedicated GWAS in a clinically-defined UK cohort (moderate grade) identified a suggestive, replicated locus near LHFPL6. Family-based exome sequencing supports polygenic genetic heterogeneity rather than a single Mendelian cause, with rare familial variants (notably AKR1C1 p.L213Q segregating in one family) reported in individual pedigrees. Collectively the evidence supports a hereditary/familial contribution to lipedema onset, frequently intertwined with hormonal transition periods, but no confirmed causal gene for primary non-syndromic lipedema has been established.
A synthesis rendered from the currently indexed evidence — versioned, not a verdict.
⚙ AI consolidation: Claude Opus 4.8 · 2026-06-02 — evidence-bounded; the AI does not opine
Answer recompiled after human curation of the claim set.
Knowledge freshness = share of the 24 indexed evidence sources from the last 5 years (newest 2026, oldest 2010) . Low freshness flags an ageing evidence base — not that the answer is wrong.
Evidence over time
consistent conflicting refining / contextual Each dot is a study, placed by year and coloured by whether the linked claim supports or contradicts the answer. As the surveillance loop runs, claim revisions and new evidence will extend this timeline.
Answer over time
Each node is a published version of the answer — open one to read the answer exactly as it stood then.
Choose a format (Vancouver default). Citing a version captures the evidence state on that date; this page shows the current version — see version history.
Consistent claims
- SCR-LIP-000004 consistent
Lipedema is a multifactorial disorder whose symptoms are closely linked to female hormonal transitions (puberty, pregnancy, menopause) and to chronic low-grade inflammation, on a polygenic predisposition.
Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) · Amato ACM, 2020 - SCR-LIP-000046 consistent
Several findings suggest a hereditary predisposition to lipedema, with frequent family history among affected women.
Brazilian Consensus Statement on Lipedema using the Delphi methodology — Amato et al. (2025) - SCR-LIP-000109 consistent
A systematic review identified four distinct pathophysiological hypotheses linking hormonal dysregulation—particularly estrogen metabolism and receptor function, growth hormone imbalance, and adipokine/leptin-related adipose stem cell alterations—to lipedema development, with possible genetic susceptibility components.
Lower limb lipoedema - male patient — Vargas (2026) · Impact of hormones on lipedema development: a systematic literature review — Lüchinger et al. (2026) - SCR-LIP-000110 consistent
Lipedema is described as an estrogen-regulated polygenic disorder that manifests almost exclusively in women, with onset at hormonal transition phases (puberty, pregnancy, menopause), family aggregation in at least 16% of cases, and a pathological ERα/ERβ receptor pattern in white adipose tissue driving site-specific lipogenesis.
Lipödem – Grundlagen und aktuelle Thesen zum Pathomechanismus — Wiedner et al. (2018) - SCR-LIP-000153 consistent
In a survey of 209 lipedema patients, symptom onset clustered in adolescence (mean age 16±9 years, 32.5% at ages 14-18), family history was common (affected grandmothers 35.4%, mothers 29.7%, aunts 23.0%), and 30.5% of premenopausal patients had sex-hormone imbalances, consistent with hormonal and hereditary contributions to lipedema onset.
New Insights on Lipedema: The Enigmatic Disease of the Peripheral Fat — Bauer et al. (2019) - SCR-LIP-000154 consistent
This critical review proposes an integrative pathomechanism in which lipedema is an estrogen-regulated polygenetic disease, citing up to 60% of cases suggesting autosomal dominant inheritance with incomplete penetrance (Child et al., 330 relatives) and manifestation paralleling feminine hormonal changes, alongside estrogen receptor differences (decreased ERα, increased ERβ in the gluteal region) and animal models (PROX1+/-, VEGFR-3 mutants).
Pathophysiological dilemmas of lipedema — Szél et al. (2014) - SCR-LIP-000141 consistent
In a Saudi cross-sectional study of 115 patients with lower-limb edema, lipedema was clinically confirmed in 71%, affected only women with mean age 38.6 years and mean BMI 30.5, with disease onset typically at ages 20-39, perceived triggers being puberty (49%), pregnancy (22%), and massive weight loss (22%), a positive family history in 46% (predominantly mothers and sisters), and 77% being previously undiagnosed.
Characteristics and Clinical Features of Patients with Lipedema in Saudi Arabia: A Cross-sectional Comprehensive Assessment — Alosaimi et al. (2024) - SCR-LIP-000157 consistent
This systematic review reports familial incidence of lipedema in 15% of first-degree female relatives consistent with X-linked dominant or autosomal dominant inheritance with incomplete penetrance, identifies an AKR1C1 missense variant (a gene involved in progesterone metabolism) as the first mutated gene in a family with primary non-syndromic lipedema, and notes hormonal/progesterone-pathway involvement.
Lipedema Research—Quo Vadis? — Ernst et al. (2023) - SCR-LIP-000219 consistent
In a series of 67 probands, 14.9% had at least one affected first-degree relative (all affected relatives female), X-chromosome linkage analysis in the largest family excluded X-linked dominant inheritance (lod scores < -2) favoring autosomal dominant inheritance with sex limitation, and onset at puberty in 55% of probands plus near-exclusive female occurrence suggested estrogen-dependent expression.
Lipedema: An inherited condition — Child et al. (2010) - SCR-LIP-000220 consistent
This narrative review reports genetic evidence (305 candidate genes via next-generation sequencing in 162 patients; 18 GWAS risk loci including VEGFA and GRB14-COBLL1 validated in UK Biobank; monogenic AKR1C1 and PIT1 mutations affecting progesterone and growth-hormone/prolactin pathways) supporting both hereditary and hormonal influences on lipedema onset.
Lipedema: Progress, Challenges, and the Road Ahead — Cifarelli (2025) - SCR-LIP-000222 consistent
This comparative narrative review reports that lipedema is almost exclusively found in women and typically begins during periods of hormonal change (puberty, pregnancy, menopause), and notes heritability/genetic markers as part of its genetics domain.
Current Mechanistic Understandings of Lymphedema and Lipedema: Tales of Fluid, Fat, and Fibrosis — Duhon et al. (2022) - SCR-LIP-000223 consistent
This multidisciplinary review reports that lipedema shows familial history in 30-89% of cases with polygenic GWAS findings (loci in CPE, ZNF25, ZNF33A linked to estrogen biology, plus VEGFA and GRB14-COBLL1, and an AKR1C1 missense variant) and that onset or worsening clusters at hormonal transitions—puberty (15.7-67.3%), pregnancy/lactation (9.5-63.1%), and menopause (1.9-21%)—with estradiol altering ERα/ERβ and PPAR-γ2 expression in lipedema-derived adipose stem cells.
Unraveling lipedema: comprehensive insights and the path to future discoveries — Faria et al. (2025) - SCR-LIP-000224 consistent
In a rigorously defined UK lipedema cohort (n=130), onset was frequently associated with hormonal changes (puberty, pregnancy, menopause), and the first dedicated GWAS identified a suggestive genetic locus (rs1409440, OR_meta 2.01, P_meta 4×10⁻⁶) upstream of LHFPL6, replicated in an independent 100,000 Genomes cohort.
Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2022) · Investigation of clinical characteristics and genome associations in the ‘UK Lipoedema’ cohort — Grigoriadis et al. (2021) - SCR-LIP-000225 consistent
This review proposes that dysregulated estrogen signaling in adipose tissue—via an increased ERα/ERβ ratio in gluteofemoral adipocytes or excessive local paracrine estrogen production by adipocyte steroidogenic enzymes—drives the excessive subcutaneous fat accumulation in lipedema, and cites whole-exome sequencing linking lipedema to variants in sex hormone genes, with onset coinciding with hormonal fluctuation periods such as puberty, pregnancy, and menopause.
Lipedema and the Potential Role of Estrogen in Excessive Adipose Tissue Accumulation — Katzer et al. (2021) - SCR-LIP-000226 consistent
A GWAS of an inferred lipedema phenotype in UK Biobank women identified 18 genome-wide significant loci (SNP heritability ~5.13%), including RSPO3 (OR=1.24), GRB14-COBLL1, VEGFA, and ADAMTS9 (some replicated in an independent clinically-diagnosed lipedema cohort), with genetic correlations to body fat, leptin levels, and age at menopause.
Genome-wide association study of a lipedema phenotype among women in the UK Biobank identifies multiple genetic risk factors — Klimentidis et al. (2023) - SCR-LIP-000215 consistent
Family-based exome sequencing of 31 individuals from 9 lipedema families identified candidate variants in 469 genes with no single gene shared across all families, supporting genetic heterogeneity rather than a Mendelian single-gene cause, with gene ontology enrichment in vasopressin receptor activity (AVPR1A, AVPR2), microfibril binding (FBN, ELN, LTBP), and patched binding (PTCH1/2, Hedgehog pathway).
A Family-Based Study of Inherited Genetic Risk in Lipedema — Morgan et al. (2024) - SCR-LIP-000238 consistent
This systematic review reports that lipedema most likely follows autosomal dominant inheritance with incomplete penetrance and sex limitation (positive family history in up to 64% of women), identifies no confirmed gene for primary non-syndromic lipedema, and catalogs syndromic associations (POU1F1A c.196C>T p.Pro24Leu; NSD1 p.Cys2175Ser/Sotos; 7q11.23 deletion/Williams-Beuren with ELN, FZD9, MLXIPL; ABCC6/PXE; ALDH18A1/cutis laxa III) plus 17 GWAS/animal-model candidate genes (e.g., LYPLAL1, TBX15, HOXC13, RSPO3, VEGFA, PROX1, VEGFR3, PRDM16).
Genetics of lipedema: new perspectives on genetic research and molecular diagnoses — Paolacci S et al. (2019) - SCR-LIP-000229 consistent
This narrative review reports that lipedema onset is associated with periods of hormonal fluctuation (puberty, pregnancy, menopause) and describes estrogen-dependent mechanisms (increased aromatase CYP19A1, estrogen-induced ZNF423 hyperproliferation), alongside a proposed female-preferential autosomal dominant inheritance pattern.
Lipedema: Insights into Morphology, Pathophysiology, and Challenges — Poojari et al. (2022) - SCR-LIP-000231 consistent
This review proposes AKR1C enzymes (AKR1C1-4) as a central biological pathway linking rare familial mutations (e.g., AKR1C1 L213Q segregating with lipedema across 3 generations, AKR1C2 Ser320PheTer2) and common regulatory polymorphisms (rs28571848, rs34477787) to lipedema through altered steroid hormone metabolism in gluteofemoral subcutaneous adipose tissue, with environmental endocrine disruptors and hormones converging on the same hereditary pathway.
From rare familial mutations to multifactorial disease: aldo-keto reductase 1C enzymes as a central biological pathway in lipedema — Vainberg et al. (2026) - SCR-LIP-000314 consistent
This narrative review proposes that lipedema involves a common genetic alteration—an imbalance of estradiol receptors (ERα > ERβ) in adipose tissue present in all cases—combined with physiological hormonal fluctuations (puberty, pregnancy, menopause), endocrine disruptors, and estrogen-dependent gynecological disorders, citing associations such as menstrual irregularities (43%) and PCOS (17%) in women with lipedema.
Hormonal Links between Lipedema and Gynecological Disorders: Therapeutic Roles of Gestrinone and Drospirenone — Viana & Câmara (2025) - SCR-LIP-000315 consistent
Whole-exome sequencing in a family with autosomal dominant nonsyndromic primary lipedema identified the AKR1C1 c.638T>A (p.L213Q) variant segregating perfectly with the disease in 3 affected members (puberty onset in all) and absent in 9 unaffected members, with molecular dynamics and QSAR predicting partial loss of 20α-HSD function that may promote lipogenesis via reduced progesterone catabolism.
Aldo-Keto Reductase 1C1 (AKR1C1) as the First Mutated Gene in a Family with Nonsyndromic Primary Lipedema — Michelini et al. (2020)
Conflicting claims
- None indexed yet.
Major uncertainty
The mode of inheritance and causal genes are unresolved: family-history prevalence estimates vary enormously (15–89%) across mostly descriptive, unadjusted cross-sectional surveys, case series, and narrative reviews with high risk of selection/recall bias. GWAS loci explain only a small fraction of heritability (~5%), several signals are only suggestive and unreplicated, and rare familial variants (e.g., AKR1C1) come from single families/case reports. No confirmed gene for primary non-syndromic lipedema exists, and whether identified loci are causal or shared with general adiposity remains unclear.
Version history
- SQ-LIP-000036 · v1.1 — 2026-06-02 — Answer recompiled after human curation of the claim set. · view this version
- SQ-LIP-000036 · v1.0 — 2026-06-02 — Decomposed from umbrella SQ-LIP-000012 (R-Q-7). · snapshot not archived
Key references
DOI:10.1590/1677-5449.202301832 · DOI:10.53347/rid-217362 · DOI:10.1007/s00404-026-08318-1 · DOI:10.1055/a-0767-6842 · DOI:10.1097/prs.0000000000006280 · DOI:10.1016/j.mehy.2014.08.011 · DOI:10.1097/gox.0000000000006173 · DOI:10.3390/jpm13010098 · DOI:10.1002/ajmg.a.33313 · DOI:10.1111/obr.13953 · DOI:10.3390/ijms23126621 · DOI:10.1038/s44324-025-00093-y · DOI:10.1371/journal.pone.0274867 · DOI:10.1101/2021.06.15.21258988 · DOI:10.3390/ijms222111720 · DOI:10.1038/s41431-022-01231-6 · DOI:10.1089/lrb.2023.0065 · DOI:10.26355/eurrev_201907_18292 · DOI:10.3390/biomedicines10123081 · DOI:10.4081/vl.2026.15495 · DOI:10.9734/jammr/2025/v37i25731 · DOI:10.3390/ijms21176264